Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study

The current study evaluated the long-term (52 week) safety and impact on symptom measures of lurasidone (with or without lithium or valproate) for the treatment of bipolar I disorder in Japanese patients.

Source: International Journal of Bipolar Disorders - August 2, 2021 Category: Psychiatry Authors: Teruhiko Higuchi, Tadafumi Kato, Mari Miyajima, Kei Watabe, Takahiro Masuda, Katsuhiko Hagi and Jun Ishigooka Tags: Research Source Type: research